<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239616</url>
  </required_header>
  <id_info>
    <org_study_id>1VEN01016</org_study_id>
    <nct_id>NCT00239616</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin</brief_title>
  <official_title>Open-label Multicenter, Pharmacokinetic Study of a Single Dose of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Regent, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Regent, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter pharmacokinetic study of HD od PD patients receiving&#xD;
      erythropoietin. Patients were administered 100mg of iron sucrose undiluted by slow IV push&#xD;
      over 5 minutes. Patients underwent serial blood draws and were subsequently followed for 7&#xD;
      days for safety endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter pharmacokinetic study of HD of adolescent PD patients&#xD;
      receiving erythropoietin. Patients between the ages of 12 and 18 were administered 100mg of&#xD;
      iron sucrose, undiluted by slow IV push over 5 minutes, and underwent serial blood draws. The&#xD;
      patients were subsequently followed for 7 days for safety endpoints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date>November 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of safety events</measure>
  </secondary_outcome>
  <enrollment>8</enrollment>
  <condition>Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iron sucrose injection USP</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 12 and 18&#xD;
&#xD;
          -  History of Chronic Renal Failure requiring HD or PD&#xD;
&#xD;
          -  Hgb &lt;/= 13 g/dL&#xD;
&#xD;
          -  Ferritin &lt; 800 ng/ml&#xD;
&#xD;
          -  TSAT &lt; 50%&#xD;
&#xD;
          -  Receiving EPO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known Sensitivity to Iron Sucrose&#xD;
&#xD;
          -  Severe Concomitant disease of the liver or cardiovascular system&#xD;
&#xD;
          -  Serious bacterial Infection&#xD;
&#xD;
          -  Pregnancy / Lactation&#xD;
&#xD;
          -  Active Hepatitis&#xD;
&#xD;
          -  Patients with Causes of iron deficiency other that Chronic Renal Failure&#xD;
&#xD;
          -  Blood Transfusion&#xD;
&#xD;
          -  Body Weight &lt; 25 KG&#xD;
&#xD;
          -  Currently being treated for Asthma&#xD;
&#xD;
          -  Received investigational drug within last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Falone, MD</last_name>
    <role>Study Director</role>
    <affiliation>American Regent, Inc.</affiliation>
  </overall_official>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <keyword>Anemia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

